JAJazeel Abdulmajeed

Jazeel Abdulmajeed

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jazeel Abdulmajeed has a total of 189 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Bariatric metabolic surgery and cancer risk: Target trial emulation using iterative time distribution matching

    by Jazeel Abdulmajeed, Zumin Shi, Manar E. Abdel-Rahman, Fakhar Shahid, Mohammed F. Alam, Mashael Al-Shafai, Muhammad E. H. Chowdhury, Abdullah Shaito, Adedayo A. Onitilo, Suhail A. Doi

    Bariatric metabolic surgery (BMS) is a common intervention for severe obesity, yet its effects on cancer risk remain unclear. Observational studies and meta-analyses yield inconsistent findings, while randomized controlled trials often lack adequate follow-up to evaluate cancer outcomes. This study aims to emulate a target trial using observational data, employing a transparent and robust methodology to address this issue. We constructed a large retrospective cohort of adults with obesity in Qatar using electronic medical records from the public health system, with data available from 2018. We developed and applied iterative time distribution matching (ITDM) which is an iterative version of prescription time distribution matching (PTDM) as an improved approach to mitigate immortal time bias. This adaptation facilitated the alignment of time-zero (T0) between BMS recipients and non-recipients. Subsequently, we applied a Cox proportional hazards regression model, controlling for confounders and prognostic covariates, for data analysis. The final study cohort comprised 124,780 individuals aged 30 years and older, including 1,465 who underwent BMS and 1,583 who developed cancer during the follow-up period. The median follow-up duration was 7.79 years (IQR: 4.89–10.85). In the confounder- and prognostic covariate-adjusted Cox model, BMS was associated with a reduced hazard of cancer (HR 0.49, 95% CI 0.31 to 0.76). Given potential residual confounding and the limited outcome data, these findings provide preliminary evidence of a protective association and should be interpreted cautiously. This approach emphasizes transparency in trial emulation design, and future studies should focus on specific cancer types and long-term outcomes as additional data become available.


  • Defining the exit meta-analysis

    by Jazeel Abdulmajeed, Luis Furuya-Kanamori, Tawanda Chivese, Chang Xu, Lukman Thalib, Suhail A.R. Doi

    Introduction: In recent decades, clinical research has seen significant advancements, both in the generation and synthesis of evidence through meta-analyses. Despite these methodological advancements, there is a growing concern about the accumulation of repetitive and redundant literature, potentially contributing to research waste. This highlights the necessity for a mechanism to determine when a meta-analysis has conclusively addressed a research question, signaling no further need for additional studies—a concept we term an “exit” meta-analysis. Methods: We introduced a convergence index, the Doi-Abdulmajeed Trial Stability (DAts) index, and a convergence plot to determine the exit status of a meta-analysis. The performance of DAts was examined through simulation and applied to two real-world meta-analyses. Results: The DAts index and convergence plot demonstrate highly effective discriminative ability across varying study scenarios. This represents the first attempt to define an exit meta-analysis using a quantitative measurement of stability (as opposed to sufficiency) and its corresponding plot. The application to real-world scenarios further validated the utility of DAts and the convergence plot in identifying a conclusive (exit) meta-analysis. Conclusion: The new development of DAts and the convergence plot provide a promising tool for investigating the conclusiveness of meta-analyses. By identifying an exit status for meta-analysis, the scientific community may be equipped to make better-informed decisions on the continuation of research on a specific topic, thereby preventing research waste and focusing efforts on areas with unresolved questions.


  • Determining the conclusiveness of a meta-analysis

    by Jazeel Abdulmajeed, Konstantinos Pateras, Polychronis Kostoulas, Suhail A.R. Doi

    The pursuit of conclusive evidence related to an unanswered foreground (decision-making) question has been the driving factor behind multiple ongoing and planned randomized controlled trials as well as meta-analyses. However, a fundamental challenge lies in establishing robust methods for ascertaining whether a collection of synthesized trials has yielded a definitive answer to that foreground question through the process of meta-analysis. This article explores the evolution of methods that attempt to address this challenge. These methods have primarily focused on defining and measuring the sufficiency and stability of evidence within a meta-analytic context. Cumulative meta-analysis and trial sequential analysis are the tools currently used, but they both come with limitations and challenges. We further discuss methods aimed at evaluating the evolution of effects over time more directly, such as the recursive cumulative meta-analysis. The latter method can be considered a better alternative, as it serves to demonstrate whether there is a true underlying treatment effect to which the meta-analysis is converging. However, recursive cumulative meta-analysis falls short of a specific indicator that establishes whether convergence has been reached. We coin the term exit for a meta-analysis where convergence can be demonstrated. Developing methods to determine the exit status of a meta-analysis is the next priority in research synthesis methods, as it will indicate that the research journey has concluded on a particular foreground question with no expectation of a different result with the addition of future trials.


  • Transforming Primary Healthcare Services with Centralized Health Intelligence: A Case Study from Qatar

    by Mujeeb C Kandy, Jazeel Abdulmajeed, Chiragkumar N Gohel, John M Gibb, Mohamed Ghaith Al-Kuwari

    Centralized Health Intelligence (CHI) represents an ecosystem where data, technology, and expertise converge to elevate the standards of healthcare services. In this case study, we explore the pivotal role of CHI in reshaping the healthcare paradigm at the Primary Health Care Corporation (PHCC) in Qatar. Adopting clinical information systems led to a wealth of data, necessitating the transformation of the conventional health information management team into the Business and Health Intelligence (BHI) Department. The establishment of a centralized enterprise data warehouse (EDW) and the use of business intelligence tools by the BHI Department further contributed to improved data governance. A meticulous Centralized Health Intelligence Framework was devised to ensure the effective use of PHCC's data assets. This framework encompasses policies and procedures related to data stewardship, information needs assessment, data classification, data privacy, and data literacy requirements. Through this study, we demonstrate how PHCC has harnessed CHI to redefine healthcare delivery by providing relevant stakeholders with easy access to advanced data analytics and data-driven decision-making tools. Implementing CHI infrastructure presents many challenges, including financial, technical, and organizational hurdles. Despite these challenges, CHI significantly benefits relevant stakeholders by providing enhanced access to health data, fostering active engagement. However, addressing data comprehension, security, and privacy concerns remains critical.


  • Open Access

    Societal health and economic burden of cardiovascular diseases in the population with type 2 diabetes in Qatar. A 10 ‐year forecasting model

    by Dina Abushanab, Daoud Al‐Badriyeh, Clara Marquina, Danny Liew, Manal Al‐Zaidan, Mohammed Ghaith Al‐Kuwari, Jazeel Abdulmajeed, Zanfina Ademi

    Aims: To predict the future health and economic burden of cardiovascular disease (CVD) in type 2 diabetes (T2D) in Qatar. Materials and Methods: A dynamic multistate model was designed to simulate the progression of fatal and non‐fatal CVD events among people with T2D in Qatar aged 40‐79 years. First CVD events [i.e. myocardial infarction (MI) and stroke] were calculated via the 2013 Pooled Cohort Equation, while recurrent CVD events were sourced from the REACH registry. Key model outcomes were fatal and non‐fatal MI and stroke, years of life lived, quality‐adjusted life years, total direct medical costs and total productivity loss costs. Utility and cost model inputs were drawn from published sources. The model adopted a Qatari societal perspective. Sensitivity analyses were performed to test the robustness of estimates. Results: Over 10 years among people with T2D, model estimates 108 195 [95% uncertainty interval (UI) 104 249‐112 172] non‐fatal MIs, 62 366 (95% UI 60 283‐65 520) non‐fatal strokes and 14 612 (95% UI 14 472‐14 744) CVD deaths. The T2D population accrued 4 786 605 (95% UI 4 743 454, 4 858 705) total years of life lived and 3 781 833 (95% UI 3 724 718‐3 830 669) total quality‐adjusted life years. Direct costs accounted for 57.85% of the total costs, with a projection of QAR41.60 billion (US$11.40 billion) [95% UI 7.53‐147.40 billion (US$2.06‐40.38 billion)], while the total indirect costs were expected to exceed QAR30.31 billion (US$8.30 billion) [95% UI 1.07‐162.60 billion (US$292.05 million‐44.55 billion)]. Conclusions: The findings suggest a significant economic and health burden of CVD among people with T2D in Qatar and highlight the need for more enhanced preventive strategies targeting this population group.


  • Top Cited Papers

    Angry scientists, angry analysts and angry novelists

    by Suhail A. Doi, Jazeel Abdulmajeed


  • Open Access

    Dynamics of Anti-S IgG Antibodies Titers after the Second Dose of COVID-19 Vaccines in the Manual and Craft Worker Population of Qatar

    by Devendra Bansal, Hassan Atia, Mashael Al Badr, Mohamed Nour, Jazeel Abdulmajeed, Amal Hasan, Noora Al-Hajri, Lina Ahmed, Rumissa Ibrahim, Reham Zamel, et al.

    There is limited seroepidemiological evidence on the magnitude and long-term durability of antibody titers of mRNA and non-mRNA vaccines in the Qatari population. This study was conducted to generate evidence on long-term anti-S IgG antibody titers and their dynamics in individuals who have completed a primary COVID-19 vaccination schedule. A total of 300 male participants who received any of the following vaccines BNT162b2/Comirnaty, mRNA-1273, ChAdOx1-S/Covishield, COVID-19 Vaccine Janssen/Johnson, or BBIBP-CorV or Covaxin were enrolled in our study. All sera samples were tested by chemiluminescent microparticle immunoassay (CMIA) for the quantitative determination of IgG antibodies to SARS-CoV-2, receptor-binding domain (RBD) of the S1 subunit of the spike protein of SARS-CoV-2. Antibodies against SARS-CoV-2 nucleocapsid (SARS-CoV-2 N-protein IgG) were also determined. Kaplan–Meier survival curves were used to compare the time from the last dose of the primary vaccination schedule to the time by which anti-S IgG antibody titers fell into the lowest quartile (range of values collected) for the mRNA and non-mRNA vaccines. Participants vaccinated with mRNA vaccines had higher median anti-S IgG antibody titers. Participants vaccinated with the mRNA-1273 vaccine had the highest median anti-S-antibody level of 13,720.9 AU/mL (IQR 6426.5 to 30,185.6 AU/mL) followed by BNT162b2 (median, 7570.9 AU/mL; IQR, 3757.9 to 16,577.4 AU/mL); while the median anti-S antibody titer for non-mRNA vaccinated participants was 3759.7 AU/mL (IQR, 2059.7–5693.5 AU/mL). The median time to reach the lowest quartile was 3.53 months (IQR, 2.2–4.5 months) and 7.63 months (IQR, 6.3–8.4 months) for the non-mRNA vaccine recipients and Pfizer vaccine recipients, respectively. However, more than 50% of the Moderna vaccine recipients did not reach the lowest quartile by the end of the follow-up period. This evidence on anti-S IgG antibody titers should be considered for informing decisions on the durability of the neutralizing activity and thus protection against infection after the full course of primary vaccination in individuals receiving different type (mRNA verus non-mRNA) vaccines and those with natural infection.


  • Open Access

    Association between Multimorbidity and COVID-19 Mortality in Qatar: A Cross-Sectional Study

    by Khalid AbouGalala, Basant Elsayed, Mohamed Elmarasi, Mona Kotob, Reham Taha, Fardous Abbasher, Ahmed Amarah, Mariam El Hamawi, Soha S. Albayat, Jazeel Abdulmajeed, et al.

    This study assessed the association between multimorbidity and mortality from COVID-19 in the Middle East and North Africa region, where such data are scarce. We conducted a cross-sectional study using data of all cases with COVID-19 reported to the Ministry of Public Health of Qatar from March to September 2020. Data on pre-existing comorbidities were collected using a questionnaire and multimorbidity was defined as having at least two comorbidities. Proportions of deaths were compared by comorbidity and multimorbidity status and multivariable logistic regression analyses were carried out. A total of 92,426 participants with a mean age of 37.0 years (SD 11.0) were included. Mortality due to COVID-19 was associated with gastrointestinal diseases (aOR 3.1, 95% CI 1.16–8.30), respiratory diseases (aOR 2.9, 95% CI 1.57–5.26), neurological diseases (aOR 2.6, 95% CI 1.19–5.54), diabetes (aOR 1.8, 95% CI 1.24–2.61), and CVD (aOR 1.5, 95% CI 1.03–2.22). COVID-19 mortality was strongly associated with increasing multimorbidity; one comorbidity (aOR 2.0, 95% CI 1.28–3.12), two comorbidities (aOR 2.8, 95% CI 1.79–4.38), three comorbidities (aOR 6.0, 95% 3.34–10.86) and four or more comorbidities (aOR 4.15, 95% 1.3–12.88). This study demonstrates a strong association between COVID-19 mortality and multimorbidity in Qatar.


  • Open Access

    Dynamics of anti-S IgG antibodies titers after the second dose of COVID 19 mRNA and non-mRNA vaccines in the manual and craft worker population of Qatar

    by Devendra Bansal, Hassan Atia, Mashael Al Badr, Mohamed Nour, Jazeel Abdulmajeed, Amal Hasan, Noora Al-Hajri, Lina Ahmed, Rumissa Ibrahim, Reham Zamel, et al.

    Background There is limited seroepidemiological evidence on the magnitude and long-term durability of antibody titers of mRNA and non-mRNA vaccines in the Qatari population. This study was conducted to generate evidence on long-term anti-S IgG antibodies titers and their dynamics in individuals who have completed a primary COVID-19 vaccination schedule. Methods A total of 300 participants who received any of the following vaccines BNT162b2/Comirnaty or mRNA-1273 or ChAdOx1-S/Covishield or COVID-19 Vaccine Janssen/Johnson or BBIBP-CorV or Covaxin were enrolled in our study. All sera samples were tested by chemiluminescent microparticle immunoassay (CMIA) for the quantitative determination of IgG antibodies to SARS-CoV-2, receptor-binding domain (RBD) of the S1 subunit of the spike protein of SARS-CoV-2. Antibodies against SARS-CoV-2 nucleocapsid (SARS-CoV-2 N-protein IgG) were also determined. Kaplan–Meier survival curves were used to compare the time from the last dose of the primary vaccination schedule to the time by which anti-S IgG antibodies titers fell into the lowest quartile (range of values collected) for the mRNA and non-mRNA vaccines. Results Participants vaccinated with mRNA vaccines had higher median anti-S IgG antibody titers. Participants vaccinated with the mRNA-1273 vaccine had the highest median anti-S-antibody level of 13720.9 AU/mL (IQR 6426.5 to 30185.6 AU/mL) followed by BNT162b2 (median, 7570.9 AU/ml; IQR, 3757.9 to 16577.4 AU/mL); while the median anti-S antibody titer for non-mRNA vaccinated participants was 3759.7 AU/mL (IQR, 2059.7-5693.5 AU/mL). The median time to reach the lowest quartile was 3.53 months (IQR, 2.2-4.5 months) and 7.63 months (IQR, 6.3-8.4 months) for the non-mRNA vaccine recipients and Pfizer vaccine recipients, respectively. However, more than 50% of the Moderna vaccine recipients did not reach the lowest quartile by the end of the follow-up period. Conclusions This evidence on anti-S IgG antibody titers, their durability and decay over time should be considered for the utility of these assays in transmission dynamics after the full course of primary vaccination.

  • Open Access

    Cardiovascular Risks and Outcome in COVID-19 Positive Patients With Cardiovascular Disease Attending Primary Health Care Corporation in Qatar: A Retrospective Cohort Study

    by Maktoum Abdul Azeez, Abdul Hakeem Hamza, Mohamed Ali Kalathingal, Sabir Abdul Karim, Mohamed Shaheen Anodiyil, Jazeel Abdulmajeed, Jeyaram Illiayaraja Krishnan, Shajitha Thekke Veettil